



IBA Cyclone[®] 70 breaks world record performances at ARRONAX in Nantes, France

IBA Cyclotron Solutions reach world record performances for ARRONAX in Nantes, successfully producing 750µA in proton beam intensity with its Cyclone[®] 70 triple particle high energy cyclotron.

Louvain-la-Neuve, November 18, 2010

Louvain-la-Neuve, Belgium, November 18th, 2010 – IBA (Ion Beam Applications S.A.) announced today, that its cyclotron solutions team working for the ARRONAX project in Nantes (France) broke world record performances with its Cyclone[®] 70 cyclotron system, surpassing 750 µA proton beam intensity at 70 MeV of beam energy over a 24 hour test.

These performances were never achieved before with a proton beam accelerator meant for biomedical applications. IBA is very proud of having met the ARRONAX' high-level requirements allowing its client to produce innovative radionuclides (such as Strontium-82-Rubidium-82, Germanium-68-Gallium-68, Copper-67, and Scandium-47 ...) for research in nuclear medicine and to perform research in radiochemistry on radiolysis (study on radiation effects on living or inert matter).

This technological premiere at ARRONAX is unique as it associates:

- High energy - 70 MeV of proton and alpha beam energy whereas the majority of cyclotrons does not exceed 30 MeV in beam energy
- Maximum beam intensity of 750 µA - offering twice the power of current 30 MeV high energy cyclotrons.
- The possibility to accelerate protons, deuterons and alpha particles whereas the majority of cyclotrons accelerate only protons.

"This is quite an achievement." said Yves Jongen, Chief Research Officer of IBA. "When you innovate to meet your client's requirements, you have to be prepared to be on the edge of risk, and this project was not different. It took energy and commitment from all parties to make this technological breakthrough possible. Hopefully it will allow ARRONAX to come in the future with discoveries that will change the face of medicine for the patient's benefit."

About Cyclone[®] 70

The Cyclone[®] 70 is a multi particle high energy industrial cyclotron. It is a variable-energy cyclotron that accelerates negative and positive ions up to 70MeV capable to deliver dual proton & deuteron particle acceleration as well as alpha particle beams. For more info, please visit our website: <http://www.iba-cyclotron-solutions.com/products-cyclo/cyclone-70>



About IBA

IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. (Molecular Imaging, Dosimetry and Particle Therapy)

Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization.

Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index.

We have leveraged our global expertise and innovation to maximize our customers' access to the most reliable radiopharmaceutical distribution network, the most advanced cyclotron solutions and the most novel research radionuclide. With our focus on Protecting, Enhancing and Saving Lives, we are committed to ensuring that our customers' ability to properly care for their patients is not compromised by their access to vital radiopharmaceuticals

About Arronax

ARRONAX which means : "Accelerator for Research in Radiochemistry and Oncology at Nantes Atlantic" aims at producing innovative radionuclides for research in nuclear medicine and at performing research in radiochemistry on radiolysis (study on radiation effects on living or inert matter).

For research in nuclear medicine, the main domain of application of Arronax is diagnostic (PET imaging) and therapeutic (radionuclide therapy) oncology. Another application is PET imaging in cardiology.

Contacts

IBA

Peter Leitner

Vice President of Sales, Cyclotron solutions

p. +32 10 201 230

e. info-cyclo@iba-group.com

w. www.iba-cyclotron-solutions.com

ARRONAX

Jacques Barbet

Chief Executive Officer

p. +33 2 28 21 21 21

e. arronax@arronax-nantes.fr

w. arronax-nantes.fr